Lv1
50 积分 2023-10-19 加入
The Lancet Breast Cancer Commission
3小时前
待确认
Antibody–drug conjugates: current status and future directions
2个月前
已完结
Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects
3个月前
已完结
Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy
7个月前
已完结
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
7个月前
已完结
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study
8个月前
已完结
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
1年前
已完结
The development of MetAP-2 inhibitors in cancer treatment
1年前
已完结
Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer
1年前
已完结
Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
1年前
已完结
皖公网安备34019202002308
